Platinum compounds represent one of the great success stories of metals in medicine. Following the serendipitous discovery of the anticancer activity of cisplatin by Rosenberg, a large number of cisplatin variants have been prepared and tested for their ability to kill cancer cells and inhibit tumor growth. These efforts continue today with increased realization that new strategies are needed to overcome issues of toxicity and resistance inherent to treatment by the approved platinum anticancer agents. One approach has been the use of so-called "non-traditional" platinum(II) and platinum(IV) compounds that violate the structure-activity relationships that governed platinum drug-development research for many years. Another is the use of specialized drug-delivery strategies. Here we describe recent developments from our laboratory involving monofunctional platinum(II) complexes together with a historical account of the manner by which we came to investigate these compounds and their relationship to previously studied molecules. We also discuss work carried out using platinum(IV) prodrugs and the development of nanoconstructs designed to deliver them in vivo.
Platinum compounds represent one of the great success stories of n class="Chemical">metals in medicine. Following the serendipitous discovery of the anticancer activity of cisplatin by Rosenberg, a large number of cisplatin variants have been prepared and tested for their ability to kill cancer cells and inhibit tumor growth. These efforts continue today with increased realization that new strategies are needed to overcome issues of toxicity and resistance inherent to treatment by the approved platinum anticancer agents. One approach has been the use of so-called "non-traditional" platinum(II) and platinum(IV) compounds that violate the structure-activity relationships that governed platinum drug-development research for many years. Another is the use of specialized drug-delivery strategies. Here we describe recent developments from our laboratory involving monofunctional platinum(II) complexes together with a historical account of the manner by which we came to investigate these compounds and their relationship to previously studied molecules. We also discuss work carried out using platinum(IV) prodrugs and the development of nanoconstructs designed to deliver them in vivo.
Authors: Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby Journal: J Biol Chem Date: 2009-12-15 Impact factor: 5.157
Authors: Shanta Dhar; Weston L Daniel; David A Giljohann; Chad A Mirkin; Stephen J Lippard Journal: J Am Chem Soc Date: 2009-10-21 Impact factor: 15.419
Authors: Kathryn M L Taylor-Pashow; Joseph Della Rocca; Zhigang Xie; Sylvie Tran; Wenbin Lin Journal: J Am Chem Soc Date: 2009-10-14 Impact factor: 15.419
Authors: Verena Pichler; Petra Heffeter; Seied M Valiahdi; Christian R Kowol; Alexander Egger; Walter Berger; Michael A Jakupec; Mathea Sophia Galanski; Bernhard K Keppler Journal: J Med Chem Date: 2012-12-17 Impact factor: 7.446
Authors: Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard Journal: Philos Trans A Math Phys Eng Sci Date: 2015-03-13 Impact factor: 4.226
Authors: Donald A McCarthy; Ahmad A Nazem; James McNeilan; Nicole L Shakerley; Ryan R Clark; María D Idelchik; Mehmet Yigit; J Andrés Melendez Journal: Exp Biol Med (Maywood) Date: 2016-07-29
Authors: Shenjie Zhang; Xiyuan Yao; Noah H Watkins; P Keegan Rose; Sofia R Caruso; Cynthia S Day; Ulrich Bierbach Journal: Angew Chem Int Ed Engl Date: 2020-09-29 Impact factor: 15.336